1 active not recruiting, 1 completed, 1 recruiting. 3 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Active not recruiting 1, Completed 1, Recruiting 1 |
| Phase 2 | 2 | Completed 1, Recruiting 1 |
Follow Lymphangioma: new trials by email Literature Review of Lymphangioma trials Research Report on Lymphangioma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| SELVA: A Phase 3 Study Evaluating QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Microcystic Lymphatic Malformations QTORIN 3.9% Rapamycin Anhydrous Gel - Microcystic Lymphatic Malformation | Phase 3 | Active not recruiting | Palvella Therapeutics, Inc. | 51 | 2024-07-31 | 2026-03-27 |
| Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation. Alpelisib, Placebo - Lymphatic Malformations | Phase 2 / Phase 3 | Recruiting | Novartis Pharmaceuticals | 232 | 2023-11-24 | 2026-10-09 |
| Study of Picibanil (OK432) Sclerotherapy in Children With Macrocystic Lymphatic Malformations picibanil - Lymphatic Malformations | Phase 2 / Phase 3 | Completed | University of Iowa | 150 | 2000-04-01 | 2015-03-25 |
Lymphatic Abnormalities (3) · Lymphangioma, Cystic (2) · Congenital Abnormalities (1) · Vascular Malformations (1)
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (3) · Hemic and Lymphatic Diseases (3) · Lymphatic Diseases (3) · Neoplasm, Lymphatic Tissue (3) · Neoplasms (3) · Neoplasms by Histologic Type (3) · Congenital Abnormalities (2) · Cardiovascular Abnormalities (1) · Cardiovascular Diseases (1)
Novartis Pharmaceuticals (1) · Palvella Therapeutics, Inc. (1) · University of Iowa (1)
United States (3) · Argentina (1) · Australia (1) · Belgium (1) · Czechia (1) · France (1) · Germany (1) · Italy (1) · Netherlands (1) · Spain (1) · Switzerland (1) · United Kingdom (1)
Joyce Teng (1) · Richard J Smith (1)
2023 (1)